Unknown

Dataset Information

0

Structure of anhydrotetracycline-bound Tet(X6) reveals the mechanism for inhibition of type 1 tetracycline destructases.


ABSTRACT: Inactivation of tetracycline antibiotics by tetracycline destructases (TDases) remains a clinical and agricultural threat. TDases can be classified as type 1 Tet(X)-like TDases and type 2 soil-derived TDases. Type 1 TDases are widely identified in clinical pathogens. A combination therapy of tetracycline and a TDase inhibitor is much needed to rescue the clinical efficacy of tetracyclines. Anhydrotetracycline is a pan-TDase inhibitor that inhibits both type 1 and type 2 TDases. Here, we present structural, biochemical, and phenotypic evidence that anhydrotetracycline binds in a substrate-like orientation and competitively inhibits the type 1 TDase Tet(X6) to rescue tetracycline antibiotic activity as a sacrificial substrate. Anhydrotetracycline interacting residues of Tet(X6) are conserved within type 1 TDases, indicating a conserved binding mode and mechanism of inhibition. This mode of binding and inhibition is distinct from anhydrotetracycline's inhibition of type 2 TDases. This study forms the framework for development of next-generation therapies to counteract enzymatic tetracycline resistance.

SUBMITTER: Kumar H 

PROVIDER: S-EPMC10106456 | biostudies-literature | 2023 Apr

REPOSITORIES: biostudies-literature

altmetric image

Publications

Structure of anhydrotetracycline-bound Tet(X6) reveals the mechanism for inhibition of type 1 tetracycline destructases.

Kumar Hirdesh H   Williford Emily E EE   Blake Kevin S KS   Virgin-Downey Brett B   Dantas Gautam G   Wencewicz Timothy A TA   Tolia Niraj H NH  

Communications biology 20230417 1


Inactivation of tetracycline antibiotics by tetracycline destructases (TDases) remains a clinical and agricultural threat. TDases can be classified as type 1 Tet(X)-like TDases and type 2 soil-derived TDases. Type 1 TDases are widely identified in clinical pathogens. A combination therapy of tetracycline and a TDase inhibitor is much needed to rescue the clinical efficacy of tetracyclines. Anhydrotetracycline is a pan-TDase inhibitor that inhibits both type 1 and type 2 TDases. Here, we present  ...[more]

Similar Datasets

| S-EPMC145453 | biostudies-literature
| S-EPMC11915366 | biostudies-literature
| S-EPMC3576927 | biostudies-literature
| S-EPMC6490184 | biostudies-literature
| S-EPMC7833170 | biostudies-literature
| S-EPMC8532604 | biostudies-literature
| S-EPMC8635130 | biostudies-literature
| S-EPMC7395757 | biostudies-literature
| S-EPMC1855585 | biostudies-literature
| S-EPMC11322121 | biostudies-literature